Stephen Connelly's most recent trade in Equillium Inc was a trade of 200,000 Common Stock done at an average price of $3.2 . Disclosure was reported to the exchange on June 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Equillium Inc | Stephen Connelly | President and CSO | Sale of securities on an exchange or to another person at price $ 3.16 per share. | 04 Jun 2026 | 200,000 | 793,000 (4%) | 1% | 3.2 | 632,760 | Common Stock |
| Equillium Inc | Stephen Connelly | President and CSO | Sale of securities on an exchange or to another person at price $ 2.94 per share. | 04 Jun 2026 | 30,975 | 762,025 (4%) | 0% | 2.9 | 91,070 | Common Stock |
| Equillium Inc | Stephen Connelly | Director, President and CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 1,150,000 | 1,150,000 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2025 | 1,025,000 | 1,025,000 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Feb 2025 | 175,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Feb 2025 | 125,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Feb 2025 | 100,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 90,000 | 90,000 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Feb 2025 | 90,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 52,500 | 52,500 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Feb 2025 | 52,500 | 0 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 42,534 | 42,534 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Feb 2025 | 42,534 | 0 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Connelly Stephen | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 7.01 per share. | 06 Oct 2021 | 5,625 | 993,000 (5%) | 0% | 7.0 | 39,418 | Common Stock |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2021 | 5,625 | 0 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.75 per share. | 06 Oct 2021 | 5,625 | 998,625 (5%) | 0% | 4.8 | 26,719 | Common Stock |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2021 | 2,467 | 0 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 7.01 per share. | 06 Oct 2021 | 2,467 | 993,000 (5%) | 0% | 7.0 | 17,288 | Common Stock |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.80 per share. | 06 Oct 2021 | 2,467 | 995,467 (5%) | 0% | 2.8 | 6,908 | Common Stock |